Welcome to our dedicated page for DENALI CAPITAL ACQ CP WTS SEC filings (Ticker: DNQWF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on DENALI CAPITAL ACQ CP WTS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into DENALI CAPITAL ACQ CP WTS's regulatory disclosures and financial reporting.
Wu Yue (Alexander) is reported as a director of Denali Capital Acquisition Corp. (ticker: SMNR). The Form 3 states the reporting person does not beneficially own any securities of the issuer and references a Power of Attorney (Exhibit 24). The statement lists the event date for the ownership report as 09/22/2025 and was signed by an attorney-in-fact on the reporting person's behalf.
Form 3 filed for Denali Capital Acquisition Corp. (SMNR) by Followwill Dorman lists the reporting relationship as a director and confirms no securities are beneficially owned as of the event date 09/22/2025. The filing is signed by an attorney-in-fact on 09/23/2025 and includes an Exhibit 24 power of attorney. This is an initial ownership statement reporting zero direct or indirect holdings.
Denali Capital Acquisition Corp. reporting person Chun Jay filed an Initial Statement of Beneficial Ownership on behalf of SEMNUR PHARMACEUTICALS, INC. The filing shows the reporting person is a director of the issuer and the Form 3 was filed in connection with an event dated 09/22/2025. The Form discloses that no securities are beneficially owned by the reporting person at the time of filing. The document includes an Exhibit 24 power of attorney and is signed by an attorney-in-fact on 09/23/2025.
Denali Capital Acquisition Corp. (SMNR) Form 3 reports initial beneficial ownership by Scilex-related entities following a business combination that closed under an amended merger agreement. Scilex, Inc. indirectly holds 193,750,000 shares of Denali Common Stock, Scilex Bio, Inc. holds 6,250,000 shares, and Scilex Holding Company directly holds 1,054,849 shares. The largest block reflects an exchange of Old Semnur shares into Denali Common Stock at an exchange ratio of 1.25 to 1. The filing documents share origins: exchanges from Series A Preferred, a pre-combination purchase, and conversion of a promissory note.
Ji Henry, Executive Chairperson and Director of Denali Capital Acquisition Corp. (Issuer listed as SMNR), filed an initial Form 3 disclosing a large stock option position tied to the company's business combination and subsequent corporate events. The filing shows a stock option exercisable through 08/30/2034 covering 21,875,000 shares of common stock at an exercise price of $1.27 per share. The option vests monthly in 1/48th installments and became exercisable following shareholder approval of an option exchange on 09/03/2025, but exercisability and related rights are suspended until a Senior Secured Promissory Note between Scilex Holding Company and Oramed Pharmaceuticals, Inc. is paid in full. The option reflects an exchange ratio of 1.25 applied when Old Semnur merged into the Issuer.